Breakthrough Solutions at the Speed of Science
Committed to restoring health and hope to patients with diseases of abnormal mineralizationSee How we help
Collaboration is the core of what we do. Driven by empathy, compassion and tireless innovation, Inozyme Pharma brings together leading talent to create life-saving therapies for patients and their families.Help us deliver hope
Patients & Health
People with rare mineralization disorders deserve effective therapies. We’re partnering with patients, their families, and their health care providers to advance life-changing therapeutic solutions and save lives.Access More
Inozyme Pharma is filling unmet medical needs by developing a targeted treatment for patients suffering from rare diseases of abnormal mineralization.
INZ-701 increases inorganic pyrophosphate (PPi) and adenosine levels by cleaving extracellular ATP throughout the body – mimicking the function of the membrane-bound ENPP1 protein.
INZ-701 is formulated for subcutaneous delivery and designed to have prolonged exposure and elimination phases, making dosing possible at infrequent intervals.
INZ-701 is a novel ERT that can target genetic and non-genetic diseases which involve low levels of PPi and adenosine – including ENPP1 Deficiency, ABCC6 Deficiency and Calciphylaxis.
Join a Clinical Trial
You are part of the solution.
We are enrolling adult patients with ENPP1 Deficiency or ABCC6 Deficiency (PXE) in the first clinical trials for a potential new treatment. With your participation, we can better understand this disease and help inform possible future treatment options.Join a clinical Trial